Výsledky vyhledávání

Akademický článek

Breast Implant Silicones and B Cell-Mediated Immune Responses: A Systematic Review of Literature

Autor: Iulianna C. Taritsa, Puja M. Jagasia, Michael Boctor, John Y.S. Kim, Megan Fracol

Publikováno v: JPRAS Open, Vol 41, Iss , Pp 353-367 (2024)

Article Summary: Introduction: Breast implants are under recent scrutiny owing to concerns about their potential for inducing immunological diseases, namely breast implant-associated anaplastic large cell lymphoma and breast implant illness. However,

Externí odkaz: https://doaj.org/article/702d76f92adf40c6b2f07e252766506f

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

A Case of Cushing’s Syndrome due to Ectopic Adrenocorticotropic Hormone Secretion from Esthesioneuroblastoma with Long Term Follow-Up after Resection

Autor: Leslee N. Matheny, Sudipa Sarkar, Hanyuan Shi, Jiun-Ruey Hu, Hannah Harmsen, Ty W. Abel, Shubhada M. Jagasia, Shichun Bao

Publikováno v: Case Reports in Endocrinology, Vol 2018 (2018)

We present a case of a 52-year-old male who developed Cushing’s Syndrome due to ectopic adrenocorticotrophic hormone (ACTH) secretion from a large esthesioneuroblastoma (ENB) of the nasal sinuses. The patient initially presented with polyuria, poly

Externí odkaz: https://doaj.org/article/8430af4b7d664454964d808a0bceafd0

Zobrazit plný text záznamu

Plný text ve formátu HTML

844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

Autor: J. Larkin, S. Dalle, M.F. Sanmamed, M. Wilson, J.C. Hassel, H. Kluger, M. Orloff, J.S. Weber, F. Graf Finckenstein, P. Hari, M. Jagasia, H. Yin, W. Shi, G. Sulur, X. Wu, V. Gontcharova, K. Lewis

Publikováno v: Annals of Oncology. 33:S935-S936

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ed66a80dc9e80c7e7d7924fd1e55a4d
https://doi.org/10.1016/j.annonc.2022.07.970

Zobrazit plný text záznamu

EP08.01-110 Trial in Progress: A Phase 2 Multicenter Study (IOV-LUN-202) of Autologous Tumor-infiltrating Lymphocyte (TIL) Cell Therapy (LN-145) in mNSCLC

Autor: J.A. Chesney, A.J. Schoenfeld, T. Wise-Draper, A. Sukari, K. He, F. Graf Finckenstein, P. Hari, M. Jagasia, S. Samakoglu, A. Leighton-Swayze, G. Chen, Y.K. Hong

Publikováno v: Journal of Thoracic Oncology. 17:S395-S396

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54eb74f6265ad45ce82dd90e3ae2b8a7
https://doi.org/10.1016/j.jtho.2022.07.682

Zobrazit plný text záznamu

883TiP A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC

Autor: J. Chesney, T. Wise-Draper, A.A. Sarnaik, F. Graf Finckenstein, P. Hari, M. Jagasia, A. Desai, A. Suzuki, X. Wu, A. Betof Warner

Publikováno v: Annals of Oncology. 33:S952

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69faf7ae0118aa91ccfa6403119261f4
https://doi.org/10.1016/j.annonc.2022.07.1009

Zobrazit plný text záznamu

799 Cutaneous leukocyte-endothelial interactions predict outcomes after hematopoietic cell transplantation

Autor: I. Saknite, J.R. Patrinely, Z. Zhao, H. Chen, T. Kim, M. Jagasia, M. Byrne, E.R. Tkaczyk

Publikováno v: Journal of Investigative Dermatology. 142:S139

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e1e2ea348dfe7604d0091f36490c9be3
https://doi.org/10.1016/j.jid.2022.05.813

Zobrazit plný text záznamu

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Autor: Richardson, P.G. Oriol, A. Beksac, M. Liberati, A.M. Galli, M. Schjesvold, F. Lindsay, J. Weisel, K. White, D. Facon, T. San Miguel, J. Sunami, K. O'Gorman, P. Sonneveld, P. Robak, P. Semochkin, S. Schey, S. Yu, X. Doerr, T. Bensmaine, A. Biyukov, T. Peluso, T. Zaki, M. Anderson, K. Dimopoulos, M. Abildgaard, N. Adler, H. Altuntas, F. Akay, O.M. Amin, B. Anagnostopoulos, A. Anderson, L. Anttila, P. Araujo, C. Arce-Lara, C. Aydin, Y. Basu, S. Battini, R. Beeker, T. Benboubker, L. Ben-Yehuda, D. Bladé, J. Blau, I.W. Boccia, R. Burke, L. Byeff, P. Cascavilla, N. Cavo, M. Chantry, A. Charles, Y. Chaudhry, A. Corso, A. Coyne, M. De Arriba, F. Delimpasi, S. Desjardins, P. Dhakal, B. Di Bartolomeo, P. Di Raimondo, F. Dürig, J. Engelhardt, M. Escoffre-Barbe, M. Esteves, G. Flogegard, M. Gabrail, N. Gamberi, B. Garrison, M. Gay, J. Gisslinger, H. Goldschmidt, H. Goncalves, C. Gressot, L. Grosicki, S. Hanna, W. Hayden, P. Henriques Bernardo, M.M. Hermann, R. Holden, V. Honkalehto, K. Huben, M. Huffman, J. Hunter, H. Hus, M. Jagasia, M. Jagganath, S. Janakiram, M. Jaiyesimi, I. Jenner, M. João, C. Johnson, P. Jurcyszyn, A. Kalayoğlu Beşişik, S. Kambhampati, S. Kanate, A. Karadoğan, I. Khojasteh, A. Kirkel, D. Komarnicki, M. Krauth, M.-T. Kuriakose, P. Larocca, A. Lauri, B. Leleu, X. Lucio, P. Luppi, M. Mangiacavalli, S. Mariette, C. Matsue, K. Mellqvist, U.-H. Mendeleeva, L. Meshad, M. Miller, C. Mohrbacher, A. Moreau, P. Morelli, A.M. Müldür, E. Naassan, A. Nahi, H. Nair, R. O'Dwyer, M. Öngören Aydin, S. Openshaw, T. O'Rourke, T. Osswald, M. Overton, L. Pati, A. Pavic, M. Pegourie, B. Pehlivan, M. Pierola, A.A. Plesner, T. Pluta, A. Rabin, N. Ramasamy, K. Rambaldi, A. Rodriguez, P. Röllig, C. Rosenblatt, J. Rosenbluth, J. Salomo, M. Samoylova, O. Sastre Moral, J. Sati, H. Selleri, C. Shafeek, S. Shinagawa, A. Sleckman, B. Smith, C. Sonmez, M. Stone, C. Streetly, M. Suzuki, K. Taetle, R. Tafuri, A. Takezako, N. Teke, H.Ü. Vapaatalo, M. Vassilopoulos, G. Verma, A. Vidito, S. Viterbo, L. Vural, F. Wang, X.S. Yağci, M. Yee, A. OPTIMISMM trial investigators

Background: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has sho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::60a64e8be607a2d94110070c4a87c17f
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3122238

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání